This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
GSK’s RSV Vaccine Moves Closer to China Approval
Regulatory filing for Arexvy has been accepted for review in China for adults aged 60 and older, where RSV affects millions each year
02/18/2026
2 min read
News
